Table 3.
Efficacy of serum and urinary microribonucleic acid‐192 in type 2 diabetes mellitus and diabetic kidney disease
| Groups | Sensitivity (%) | Specificity (%) | YI | Cut‐off values | ||||
|---|---|---|---|---|---|---|---|---|
| S | U | S | U | S | U | S | U | |
| A: NC + NA + MA + LA | 93.3 | 92.9 | 74.5 | 100 | 0.678 | 0.929 | 0.4067 | 3.1271 |
| B: NC + NA + MA | 64.6 | 90.6 | 78.5 | 77.3 | 0.431 | 0.679 | 0.3373 | 5.5147 |
| C: NC + NA + LA | 85.5 | 96.2 | 56.7 | 59.8 | 0.422 | 0.56 | 0.1097 | 9.3778 |
| D: NA + MA | 70.8 | 97.4 | 65.3 | 68.2 | 0.361 | 0.656 | 0.2916 | 4.1065 |
| E: MA + LA | 69.4 | 80.8 | 56.7 | 47.4 | 0.261 | 0.282 | 0.1097 | 9.4381 |
Youden Index (YI) = sensitivity + specificity‐1. LA, large amount of albuminuria; MA, microalbuminuria; NA, normal albuminuria; NC, normal controls; S, serum; U, urine.